Clinical Trial

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Based on preclinical data from the Lim lab (WUSM), the investigators hypothesize that IRAK4 inhibition cripples tumor-intrinsic survival signaling and effectively overcomes the desmoplastic and immune-suppressive tumor microenvironment (TME) to render chemo- and immunotherapies effective in GI malignancy. Therefore, this trial is designed to evaluate the combination of emavusertib (CA-4948) and standard chemoimmunotherapy in untreated advanced or metastatic biliary tract cancer (BTC).
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-04
Trial Details
NCT Number NCT07107750
Lead Sponsor Washington University School of Medicine
Collaborators: Curis, Inc.
Conditions Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma
Enrollment 48 participants
Start Date 2026-03-27
Primary Completion 2030-06-30 (estimated)
Study Completion 2032-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-03